Dr. Gaurav Mahesh Doshi

M. Pharm. Ph.D. PGDCRPR

HoD, Pharmacology

Specialization: Pharmacology, Toxicology and Therapeutics

Experience:
Academic: 15 Years & 3 Months
Industry: 3 Years & 11 months

Thrust Research areas: Immunology, CNS, Diabetes, wound healing,Studies Isolation, elucidation and quantification of plant extracts and theirbiological activities.

Awards:

1. BNCP Shining Stars Award (Appreciation Award 2022-2023) on 28th March 2023 by SVKM’s Dr. Bhanuben Nanavati College of Pharmacy, Mumbai.
2. Awarded with Dr. APJ Abdul Kalam Lifetime Achievement National Award for your remarkable achievements in the field of Teaching, Research and Publications, International Institute of economic reforms and research, Bangalore on 23/04/2022.
3. Awarded Best Performing Faculty for the year 2021-2022 for remarkable overall performance by SVKM’s Dr. Bhanuben Nanavati College of Pharmacy on Annual Day on 12/04/2022.
4. Awarded “Excellence in Teaching Award” by Agro-Environmental Development Society (AEDS) Rampur, Uttar Pradesh, India for his outstanding contribution in the field of Pharmacy on the occasion of the 5th International Conference on “Advances in Agriculture, Environmental and Biosciences for Sustainable Development (AAEBSD- 2021)” held on 05/08/2021- 07/08/2021
5. Awarded Smt. Jethibai Hirdaram Jagtiani Award for Securing the Highest Marks at M. Pharm. Science Exam by Prin. K. M. Kundnani College of Pharmacy.

Total Publications: 95

Cumulative impact factor of Clarivate/Thompson Reuter: 113.93

Books/Book chapters: 06

Google Scholar: https://scholar.google.co.in/citations?user=BamE3hUAAAAJ&hl=en

ORCID Id: https://orcid.org/0000-0002-8490-0705

Researcher ID: AAV-3681-2021

Scopus Author ID: 47860958900

Recent Publications-

1. New Insights in Psoriasis Managementusing Herbal Drug Nanocarriers, Current Pharmaceutical Design 2024; 30, 32 (4):2550-2561. (Impact Factor: 2.6)
2. Revolutionizing InfertilityManagement through Novel Peptide-based Targets, Current Protein & PeptideScience 2024, (25),9: 737-751. (ImpactFactor: 1.9)
3. Epigenetic aging in major depressivedisorder: Clocks, mechanisms and therapeutic perspectives, European Journal ofPharmacology, Volume 978, 2024,176757 (Impactfactor: 4.2).
4. Zebrafish Experimental Animal Modelsfor AD: A Comprehensive Review. Curr Rev Clin Exp Pharmacol. 2024; 19(4):295-311. (Impact factor: 1.1).
5. Unraveling the Role of the GlycogenSynthase Kinase-3ß, Bruton's Tyrosine Kinase, and Sphingosine 1 Phosphate Pathwaysin Multiple Sclerosis. Endocr Metab Immune Disord Drug Targets. 2024; 24 (10):1131-1145. Jan 26. (Impact factor: 1.9).
6. Deciphering the Role of PeroxisomeProliferator-activated Receptor a and Phosphodiesterase Type 5 Targets inAlzheimer's Disease, CNS & Neurological Disorders - Drug Targets 2024; 23(8):956-970. (Impact factor: 3.0).
7. Glutamate Receptors and C-ABLInhibitors: A New Therapeutic Approach for Parkinson's Disease, Central NervousSystem Agents in Medicinal Chemistry 2024; 24 (1): 22-24 (Scopus).
8. New Promising Routes in PepticUlcers: Toll-like Receptors and Semaphorins, Endocrine, Metabolic & ImmuneDisorders - Drug Targets 2024; 24 (8): 865-878. (Impact factor: 1.9).
9. Enhancing Gastric Ulcer Management:Novel Insights from Terazosin-Pantoprazole Combination Therapy. Indian Drugs;61 (01) January 2024: 77-85 [ScopusIndexed].
10. A Cross Talk on the Role ofContemporary Biomarkers in Depression. Biomarkers. 2024 Jan 23:1-25. (Impact factor: 2.6)
11. Terazosin produces anantidepressant-like effect in mice exposed to chronic unpredictable mild stressbehavioral alteration, Neuroscience Letters, Volume 822, 2024, 137653. (Impact factor: 2.5)
12. Viral therapy for targeted drugdelivery to cancers: Recent advances, clinical and regulatory perspectives, Journal of Drug Delivery Science and Technology,Volume 92, 2024, 105365. (Impact factor:5).

Research/ Sponsored projects:

Government: 12 (INR 18.96 Lakhs)

Industry Project completed: 01 (INR 92,000/-)

Invited talks: 03

Research students:

M. Pharm: 36

Conferences attended: 

SWAYAMMOOCS and NITTTR: 24

AICTE-FDP: 24

Coursera:11

Workshopsattended: 22

Seminarsattended: 42

Paper Presentations: 18

Professional Membership:

Life Member of Association of Pharmaceutical Teachers of India

Contact:

E-mail: gaurav.doshi@bncp.ac.in

Tel. 022-4233 2052 (Ext 2163)

LinkedIn profile link:  https://www.linkedin.com/in/dr-gaurav-doshi-07173720/

Mr. Angel Godad

M. Pharm. Ph.D. (Pursuing)

Specialization: Pharmacology

Qualification: M. Pharm.

Designation: Assistant Professor

 Experience:

Academic: 13 years

Thrust research areas:   

Pharmacotherapeutics, Inflammopharmacology, Ethnopharmacology

 Research/ Sponsored projects:

Government: 03

Publications: 

Publications: 12

Recent Publications-

1. Ansari A; Bhatia N; Gharat Sankalp; Godad Angel & Doshi Gaurav, “Exploring Cytokines as Potential Target in Peptic Ulcer Disease: A Systematic Update. Endocrine, Metabolic & Immune Disorders - Drug Targets, January 2023, 23(1), 21-34. (IF: 2.387)
2. Ansari A; Bhatia N; Gharat Sankalp;  Godad Angel & Doshi Gaurav , Exploring Cytokines as Potential Target in Peptic Ulcer Disease: A Systematic Update Endocrine, Metabolic & Immune Disorders - Drug Targets, August  2022, 23(1), 21-31(IF:2.895)Review article(Online ahead of print) . 10.2174/1871530322666220829142124
3. Shah P; Siddique A; Thakkar A; Gharat Sankalp Godad Angel; Kale Pravin & Doshi Gaurav, An update on novel therapeutic intervention in Rheumatoid arthritis. International Immunopharmacology, August 2022, 109, 1-16(IF: 5.714) Review article.  10.1016/j.intimp.2022.108794
4. Mhapankar N; Siddique A.; Doshi Gaurav; Godad Angel & Zine Sandip, Deciphering the Role of ß-Lactamase Inhibitors, Membrane Permeabilizers and Efflux Pump Inhibitors as Emerging Targets in Antibiotic Resistance. Indian Journal of Microbiology, October 2022, 62, 524-530 (IF: 2.21) Review article https://link.springer.com/article/10.1007/s12088-022-01045-6
5. Kelkar Siddesh, Nailwal Namrata, Bhatia Yogesh Nirav, Doshi Gaurav, Sathaye Sadhana & Godad Angel, An Update on Proficiency of Voltage-gated Ion Channel Blockers in the Treatment of Inflammation-associated Diseases, Current Drug Targets, November 2022; 23(14). 1290-1303. (IF: 2.937) Review article 10.2174/1389450123666220819141827
6. Doshi Gaurav; Sathaye S; Bhatia N & Godad Angel, Unraveling the immunomodulatory potential of cyprinus carpio. Journal of Young Pharmacists April 2022, 14(2), 1-4 Review Article. doi:10.5530/jyp.2022.14.30. 
7. Nailwal N; Bhatia N; Ali A;Ansari A; Raheja Radhika ; Godad Angel & Doshi Gaurav, in the book titled , Marine Antioxidants Preparations, Syntheses, and Applications, chapter named Antioxidants obtained from marine sources 45, 2022, Elsevier, ISBN: 978-0-323-95086-2. https://doi.org/10.1016/B978-0-323-95086-2.00011-4 (Book Chapter). 

Conferences/Workshops/Seminars attended: 25

Professional memberships: 03

Contact details:

E-mail: angel.godad@bncp.ac.in

Tel. 022-4233 2052 (Ext: 2060)

Swapnil Rijanlal Raut 

 M. S. Pharm. (Pharmacology & Toxicology)

Specialization: Pharmacology

Experience:

Academic: 1.5 years

Thrust research areas:   

Neurobehavioral studies and Molecular biological techniques

Publications: 06

Conferences/Workshops/Seminars attended: 5

Professional memberships: 03

List of Publications:

“Migraine and Ischemic Stroke: Deciphering the Bidirectional Pathway” (Published in ACS Chemical Neuroscience; IF: 3.68) DOI: https://doi.org/10.1021/acschemneuro.0c00137. 

“The Role of Inflammasomes in Atherosclerosis and Stroke Pathogenesis” (Published in Current Pharmaceutical Design; IF: 2.8) DOI: 10.2174/1381612826666200427084949. 

“Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases” (Published in Immunology; IF: 5.01) DOI: https://doi.org/10.1111/imm.13264. 

“Cerebro-Renal Interaction and Stroke” (Published in European Journal of Neuroscience; IF:3.68) DOI: 10.1111/ejn.14983. 

“Post-stroke depression: Chaos to exposition” (Published in Brain Research Bulletin) DOI: 10.1016/j.brainresbull.2020.12.012. 

“Polymeric nanomaterials in neuroscience” (Published in book Advances in Polymeric Nanomaterials for Biomedical Application, Elsevier) DOI: https://doi.org/10.1016/B978-0-12-814657-6.00006-9. 

Contact details:

E-mail: SwapnilRaut753@gmail.com

Tel. 022-4233 2052 (Ext: 2060)

LinkedIn: linkedin.com/in/swapnil-r-a-144a593

Ms. Sonam R. Tanwar 

M. Pharm.Ph.D. (Pursuing)

Thrustresearch areas:  

Neurologicaldisorders, Diabetes and its complications

Research:

Publications: 2 

GoogleScholar link: https://scholar.google.com/citations?hl=en&user=4H9f430AAAAJ

RecentPublications

Sonam Tanwar, Vaibhavi Garge, Determination of Pharmacological Drug Interaction of Glibenclamide and Hippophae rhamnoides in Streptozotocin (STZ) induced Diabetes Mellitus in Rat Model. IJPPR. Human, 2022; 25 (2), 538-562

Nikam D, Tanwar S, Kute A, Lokhande S and Yadav R. Synthesis and Evaluation of Novel Chemical Entities as Anti-Breast Cancer Agents, Indian Drugs, 2019; 56 (12), 28-31

Conferencesattended: 3

Workshopsattended: 2

Contactdetails:

E-mail:sonamtan1995@gmail.com

Tel.022-4233 2052 

LinkedInprofile link: https://www.linkedin.com/in/sonam-tanwar-83127618b/